ATE292472T1 - Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung - Google Patents
Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlungInfo
- Publication number
- ATE292472T1 ATE292472T1 AT00907633T AT00907633T ATE292472T1 AT E292472 T1 ATE292472 T1 AT E292472T1 AT 00907633 T AT00907633 T AT 00907633T AT 00907633 T AT00907633 T AT 00907633T AT E292472 T1 ATE292472 T1 AT E292472T1
- Authority
- AT
- Austria
- Prior art keywords
- polynucleotides
- cancer treatment
- casb616
- polypeptides
- casb616 polypeptides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 title abstract 2
- 108091033319 polynucleotide Proteins 0.000 title abstract 2
- 239000002157 polynucleotide Substances 0.000 title abstract 2
- 229920001184 polypeptide Polymers 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000029742 colonic neoplasm Diseases 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/82—Colon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9905124.5A GB9905124D0 (en) | 1999-03-05 | 1999-03-05 | Novel compounds |
| PCT/EP2000/001587 WO2000053216A2 (en) | 1999-03-05 | 2000-02-28 | Use of casb616 polypeptides and polynucleotides for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE292472T1 true ATE292472T1 (de) | 2005-04-15 |
Family
ID=10849064
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00907633T ATE292472T1 (de) | 1999-03-05 | 2000-02-28 | Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20050129717A1 (de) |
| EP (2) | EP1162993B1 (de) |
| JP (1) | JP2002538218A (de) |
| KR (1) | KR20010102507A (de) |
| CN (1) | CN1374869A (de) |
| AT (1) | ATE292472T1 (de) |
| AU (1) | AU766789B2 (de) |
| BR (1) | BR0008784A (de) |
| CA (1) | CA2362370A1 (de) |
| CY (1) | CY1105585T1 (de) |
| CZ (1) | CZ20013189A3 (de) |
| DE (1) | DE60019273T2 (de) |
| ES (1) | ES2238026T3 (de) |
| GB (1) | GB9905124D0 (de) |
| HK (1) | HK1043729B (de) |
| HU (1) | HUP0200186A2 (de) |
| IL (1) | IL145046A0 (de) |
| NO (1) | NO20014292L (de) |
| NZ (1) | NZ513837A (de) |
| PL (1) | PL354143A1 (de) |
| PT (1) | PT1162993E (de) |
| TR (1) | TR200102577T2 (de) |
| WO (1) | WO2000053216A2 (de) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001271621A1 (en) * | 2000-06-28 | 2002-01-08 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating colon cancer |
| SI2266603T1 (sl) * | 2000-10-18 | 2012-12-31 | Glaxosmithkline Biologicals S.A. | Tumorska cepiva |
| CN1446583A (zh) * | 2002-11-29 | 2003-10-08 | 帕弗瑞生物技术(北京)有限公司 | 一种肿瘤免疫治疗及预防性疫苗的组成、制备、应用方案 |
| EP2478912B1 (de) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Konjugate von Auristatin mit gegen HER2- oder CD22-gerichtete Antikörper und deren therapeutische Verwendung |
| NZ579482A (en) | 2004-06-01 | 2011-02-25 | Genentech Inc | Antibody drug conjugates and methods |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| JP2013504585A (ja) | 2009-09-09 | 2013-02-07 | セントローズ， エルエルシー | 細胞外標的化薬物複合体 |
| SI2528625T1 (sl) | 2010-04-15 | 2013-11-29 | Spirogen Sarl | Pirolobenzodiazepini in njihovi konjugati |
| CA2799540A1 (en) | 2010-06-08 | 2011-12-15 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| US20120121615A1 (en) | 2010-11-17 | 2012-05-17 | Flygare John A | Alaninyl maytansinol antibody conjugates |
| US8679767B2 (en) | 2011-05-12 | 2014-03-25 | Genentech, Inc. | Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides |
| BR112014009050B1 (pt) | 2011-10-14 | 2022-06-21 | Medimmune Limited | Conjugado anticorpo-fármaco de pirrolbenzodiazepinas, composição farmacêutica que compreende o mesmo, bem como compostos de pirrolbenzodiazepinas |
| WO2013130093A1 (en) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Biomarkers for treatment with anti-tubulin chemotherapeutic compounds |
| EP2906296B1 (de) | 2012-10-12 | 2018-03-21 | ADC Therapeutics SA | Pyrrolobenzodiazepin-antikörper-konjugate |
| HRP20182129T1 (hr) | 2012-10-12 | 2019-02-08 | Adc Therapeutics Sa | Konjugati protutijelo - pirolobenzodiazepin |
| RS57694B1 (sr) | 2012-10-12 | 2018-11-30 | Adc Therapeutics Sa | Pirolobenzodiazepin - anti-psma konjugati antitela |
| EP2906297B1 (de) | 2012-10-12 | 2017-12-06 | ADC Therapeutics SA | Pyrrolobenzodiazepin-antikörper-konjugate |
| JP6392765B2 (ja) | 2012-10-12 | 2018-09-19 | エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ | ピロロベンゾジアゼピン−抗体結合体 |
| MX338711B (es) | 2012-10-12 | 2016-04-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| ES2680153T3 (es) | 2012-10-12 | 2018-09-04 | Adc Therapeutics Sa | Conjugados de anticuerpos anti-PSMA-pirrolobenzodiazepinas |
| CN105189507A (zh) | 2012-12-21 | 2015-12-23 | 斯皮罗根有限公司 | 吡咯并苯并二氮杂卓及其结合物 |
| CN110627797A (zh) | 2012-12-21 | 2019-12-31 | 麦迪穆有限责任公司 | 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物 |
| AU2014229529B2 (en) | 2013-03-13 | 2018-02-15 | Medimmune Limited | Pyrrolobenzodiazepines and conjugates thereof |
| MX362970B (es) | 2013-03-13 | 2019-02-28 | Medimmune Ltd | Pirrolobenzodiazepinas y conjugados de las mismas. |
| TWI680766B (zh) | 2013-03-13 | 2020-01-01 | 英商梅迪繆思有限公司 | 吡咯并苯并二氮呯及其共軛物 |
| BR112016002829A2 (pt) | 2013-08-12 | 2017-09-19 | Genentech Inc | Composto e processo para preparar o composto de conjugado anticorpo-¿droga, composição farmacêutica, método de tratamento do câncer, kit para o tratamento do câncer, intermediário ligante¿-droga, porção e composto de porção droga de dímero cbi |
| GB201317982D0 (en) | 2013-10-11 | 2013-11-27 | Spirogen Sarl | Pyrrolobenzodiazepines and conjugates thereof |
| WO2015052535A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| WO2015052534A1 (en) | 2013-10-11 | 2015-04-16 | Spirogen Sàrl | Pyrrolobenzodiazepine-antibody conjugates |
| EP3054983B1 (de) | 2013-10-11 | 2019-03-20 | Medimmune Limited | Pyrrolobenzodiazepin-antikörper-konjugate |
| EP3082876B1 (de) | 2013-12-16 | 2018-01-17 | Genentech, Inc. | 1-(chlormethyl)-2,3-dihydro-1h-benzo[e]indoldimer-antikörper-wirkstoff-konjugatverbindungen und verfahren zur verwendung und behandlung |
| JP6671292B2 (ja) | 2013-12-16 | 2020-03-25 | ジェネンテック， インコーポレイテッド | ペプチド模倣化合物及びその抗体−薬物コンジュゲート |
| WO2015095227A2 (en) | 2013-12-16 | 2015-06-25 | Genentech, Inc. | Peptidomimetic compounds and antibody-drug conjugates thereof |
| EP3193940A1 (de) | 2014-09-10 | 2017-07-26 | Medimmune Limited | Pyrrolobenzodiazepine und konjugate daraus |
| GB201416112D0 (en) | 2014-09-12 | 2014-10-29 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| SG11201701128YA (en) | 2014-09-12 | 2017-03-30 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| WO2016040825A1 (en) | 2014-09-12 | 2016-03-17 | Genentech, Inc. | Anthracycline disulfide intermediates, antibody-drug conjugates and methods |
| CN107073136A (zh) | 2014-09-17 | 2017-08-18 | 健泰科生物技术公司 | 吡咯并苯并二氮杂卓及其抗体二硫化物偶联物 |
| CN107148285B (zh) | 2014-11-25 | 2022-01-04 | Adc治疗股份有限公司 | 吡咯并苯并二氮杂䓬-抗体缀合物 |
| AU2015358532C1 (en) | 2014-12-03 | 2020-10-29 | Genentech, Inc. | Quaternary amine compounds and antibody-drug conjugates thereof |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| GB201506402D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| CR20180243A (es) | 2015-10-02 | 2018-07-31 | Genentech Inc | Conjugados de anticuerpo-fármaco de pirrolobenzodiazepina y métodos de uso |
| MA43354A (fr) | 2015-10-16 | 2018-08-22 | Genentech Inc | Conjugués médicamenteux à pont disulfure encombré |
| EP3365025B1 (de) | 2015-10-20 | 2020-07-15 | Genentech, Inc. | Calicheamicin-antikörper-arzneimittelkonjugate und verfahren zur verwendung |
| GB201601431D0 (en) | 2016-01-26 | 2016-03-09 | Medimmune Ltd | Pyrrolobenzodiazepines |
| GB201602356D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| GB201602359D0 (en) | 2016-02-10 | 2016-03-23 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN108700598A (zh) | 2016-03-25 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 多路总抗体和抗体缀合的药物量化测定法 |
| GB201607478D0 (en) | 2016-04-29 | 2016-06-15 | Medimmune Ltd | Pyrrolobenzodiazepine Conjugates |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| EP3465221B1 (de) | 2016-05-27 | 2020-07-22 | H. Hoffnabb-La Roche Ag | Bioanalytisches verfahren zur charakterisierung von ortsspezifischen antikörper-wirkstoff-konjugaten |
| WO2017214024A1 (en) | 2016-06-06 | 2017-12-14 | Genentech, Inc. | Silvestrol antibody-drug conjugates and methods of use |
| CN109689111B (zh) | 2016-08-11 | 2024-04-05 | 基因泰克公司 | 吡咯并苯并二氮杂䓬前药及其抗体缀合物 |
| JP7050770B2 (ja) | 2016-10-05 | 2022-04-08 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 抗体薬物コンジュゲートの調製方法 |
| GB201617466D0 (en) | 2016-10-14 | 2016-11-30 | Medimmune Ltd | Pyrrolobenzodiazepine conjugates |
| GB201702031D0 (en) | 2017-02-08 | 2017-03-22 | Medlmmune Ltd | Pyrrolobenzodiazepine-antibody conjugates |
| RS61795B1 (sr) | 2017-02-08 | 2021-06-30 | Adc Therapeutics Sa | Konjugati pirolobenzodiazepin antitela |
| CN110582505B (zh) | 2017-04-18 | 2021-04-02 | 免疫医疗有限公司 | 吡咯并苯并二氮杂*缀合物 |
| WO2018193102A1 (en) | 2017-04-20 | 2018-10-25 | Adc Therapeutics Sa | Combination therapy with an anti-axl antibody-drug conjugate |
| CA3064804A1 (en) | 2017-06-14 | 2018-12-20 | Adc Therapeutics Sa | Dosage regimes for the administration of an anti-cd19 adc |
| KR102270107B1 (ko) | 2017-08-18 | 2021-06-30 | 메디뮨 리미티드 | 피롤로벤조디아제핀 컨쥬게이트 |
| EP3684773B1 (de) | 2017-09-20 | 2026-04-29 | pH Pharma Co., Ltd. | Thailanstatinanaloga |
| US11068545B2 (en) | 2017-11-17 | 2021-07-20 | Battelle Memorial Institute | Spatial identification of assets using n-dimensional asset identifiers |
| GB201803342D0 (en) | 2018-03-01 | 2018-04-18 | Medimmune Ltd | Methods |
| GB201806022D0 (en) | 2018-04-12 | 2018-05-30 | Medimmune Ltd | Pyrrolobenzodiazepines and conjugates thereof |
| GB201814281D0 (en) | 2018-09-03 | 2018-10-17 | Femtogenix Ltd | Cytotoxic agents |
| JP7708662B2 (ja) | 2018-10-24 | 2025-07-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | コンジュゲート化された化学的分解誘導物質および使用方法 |
| JP2022513198A (ja) | 2018-12-10 | 2022-02-07 | ジェネンテック， インコーポレイテッド | Ｆｃ含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド |
| GB201901197D0 (en) | 2019-01-29 | 2019-03-20 | Femtogenix Ltd | G-A Crosslinking cytotoxic agents |
| CN113631560B (zh) | 2019-03-15 | 2025-02-18 | 麦迪穆有限责任公司 | 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物 |
| GB2597532A (en) | 2020-07-28 | 2022-02-02 | Femtogenix Ltd | Cytotoxic compounds |
| EP4426727A2 (de) | 2021-11-03 | 2024-09-11 | Hangzhou Dac Biotech Co., Ltd. | Spezifische konjugation eines antikörpers |
| WO2024138128A2 (en) | 2022-12-23 | 2024-06-27 | Genentech, Inc. | Cereblon degrader conjugates, and uses thereof |
| KR20260012304A (ko) | 2023-04-17 | 2026-01-26 | 피크 바이오, 인크. | 항체 및 항체-약물 접합체 및 사용 방법 및 합성 공정 및 중간체 |
| WO2026006689A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Bcl-xl degrader antibody conjugates and uses thereof |
| WO2026006688A2 (en) | 2024-06-28 | 2026-01-02 | Firefly Bio, Inc. | Degrader antibody conjugates and uses thereof |
| CN120324603B (zh) * | 2025-04-28 | 2025-12-23 | 中奥生物医药技术(广东)有限公司 | 一种Caerin多肽联合树突状细胞疫苗在制备治疗乳腺癌药物中的应用 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE293989T1 (de) * | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
-
1999
- 1999-03-05 GB GBGB9905124.5A patent/GB9905124D0/en not_active Ceased
-
2000
- 2000-02-28 NZ NZ513837A patent/NZ513837A/xx unknown
- 2000-02-28 CZ CZ20013189A patent/CZ20013189A3/cs unknown
- 2000-02-28 EP EP00907633A patent/EP1162993B1/de not_active Expired - Lifetime
- 2000-02-28 EP EP04076929A patent/EP1466616A3/de not_active Withdrawn
- 2000-02-28 HK HK02103796.8A patent/HK1043729B/en not_active IP Right Cessation
- 2000-02-28 PL PL00354143A patent/PL354143A1/xx not_active Application Discontinuation
- 2000-02-28 DE DE60019273T patent/DE60019273T2/de not_active Expired - Fee Related
- 2000-02-28 WO PCT/EP2000/001587 patent/WO2000053216A2/en not_active Ceased
- 2000-02-28 JP JP2000603705A patent/JP2002538218A/ja active Pending
- 2000-02-28 CN CN00807172A patent/CN1374869A/zh active Pending
- 2000-02-28 BR BR0008784-0A patent/BR0008784A/pt not_active IP Right Cessation
- 2000-02-28 KR KR1020017011300A patent/KR20010102507A/ko not_active Ceased
- 2000-02-28 CA CA002362370A patent/CA2362370A1/en not_active Abandoned
- 2000-02-28 HU HU0200186A patent/HUP0200186A2/hu unknown
- 2000-02-28 PT PT00907633T patent/PT1162993E/pt unknown
- 2000-02-28 TR TR2001/02577T patent/TR200102577T2/xx unknown
- 2000-02-28 ES ES00907633T patent/ES2238026T3/es not_active Expired - Lifetime
- 2000-02-28 AT AT00907633T patent/ATE292472T1/de not_active IP Right Cessation
- 2000-02-28 IL IL14504600A patent/IL145046A0/xx unknown
- 2000-02-28 AU AU29153/00A patent/AU766789B2/en not_active Ceased
-
2001
- 2001-09-04 NO NO20014292A patent/NO20014292L/no not_active Application Discontinuation
-
2004
- 2004-11-09 US US10/984,521 patent/US20050129717A1/en not_active Abandoned
-
2005
- 2005-05-18 CY CY20051100614T patent/CY1105585T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU766789B2 (en) | 2003-10-23 |
| PL354143A1 (en) | 2003-12-29 |
| JP2002538218A (ja) | 2002-11-12 |
| HUP0200186A2 (en) | 2002-05-29 |
| ES2238026T3 (es) | 2005-08-16 |
| TR200102577T2 (tr) | 2004-09-21 |
| CY1105585T1 (el) | 2010-07-28 |
| WO2000053216A3 (en) | 2001-01-11 |
| HK1043729B (en) | 2005-11-04 |
| EP1162993B1 (de) | 2005-04-06 |
| AU2915300A (en) | 2000-09-28 |
| GB9905124D0 (en) | 1999-04-28 |
| CN1374869A (zh) | 2002-10-16 |
| DE60019273D1 (de) | 2005-05-12 |
| IL145046A0 (en) | 2002-06-30 |
| NO20014292L (no) | 2001-10-29 |
| EP1466616A2 (de) | 2004-10-13 |
| EP1162993A2 (de) | 2001-12-19 |
| PT1162993E (pt) | 2005-06-30 |
| NZ513837A (en) | 2003-02-28 |
| HK1043729A1 (en) | 2002-09-27 |
| CZ20013189A3 (cs) | 2002-02-13 |
| BR0008784A (pt) | 2001-12-26 |
| US20050129717A1 (en) | 2005-06-16 |
| DE60019273T2 (de) | 2006-01-19 |
| NO20014292D0 (no) | 2001-09-04 |
| CA2362370A1 (en) | 2000-09-14 |
| WO2000053216A2 (en) | 2000-09-14 |
| KR20010102507A (ko) | 2001-11-15 |
| EP1466616A3 (de) | 2004-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE292472T1 (de) | Verwendung von casb616 polypeptiden und polynukleotiden zur krebsbehandlung | |
| GB2317891C (en) | Human Telomerase Catalytic Subunit | |
| IL153052A0 (en) | Nrg-2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods | |
| HUP0300054A1 (hu) | Daganatspecifikus állati fehérjék | |
| DE602004020266D1 (de) | Therapeutische und diagnostische anti-hsp 70-antikörper | |
| AU2002246922A1 (en) | Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides | |
| DE60031383D1 (de) | Verwendung von casb618 polynucleotide und polypeptide | |
| DE60326931D1 (de) | In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren | |
| BR0009358A (pt) | Compostos | |
| ATE286071T1 (de) | Mittel zur therapie von menschlichen erkrankungen,insbesondere für die therapie von tumoren wie kolonkarzinomen und melanomen oder zur geweberegeneration und förderung des haarwuchses | |
| WO2000043509A3 (en) | Polynucleotides and their applications in diagnostics | |
| WO2001023417A3 (en) | Human tumor-associated lak-4p related polynucleotides and polypeptides and their uses | |
| AU2003208871A8 (en) | Novel retina specific human proteins wdr17, net01, protein kinase a203, protein kinase mak a194, protein a105, protein a106 and c12orf3variants | |
| GB0121818D0 (en) | Proteins, genes and their use for diagnosis and treatment of breast cancer | |
| GB0128742D0 (en) | Nucleic acid molecules polypeptides and uses therefor including diagnosis and treatment of breast cancer | |
| DE60226451D1 (de) | Menschliches protoonkogen kg-20 und darin codiertes protein |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1162993 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |